Watch More Highlights
Amber Koehler, MPAS, PA-C, of Mayo Clinic, reports on the favorable outcomes and better tolerability of nivolumab (N) with doxorubicin, vinblastine, and dacarbazine (AVD) compared with brentuximab vedotin (BV) with AVD in patients with newly diagnosed advanced stage Hodgkin Lymphoma (Abstract 181).